Although much preclinical evidence, as highlighted in this review, showed definitive evidence of Hsp90 regulation and its inhibition by the individual model of GBM and neurodegeneration, studies on the combined model of GBM and neurodegeneration or GBM-induced neurodegeneration remain undetermined and critical for the concurrent treatment of Hsp90 inhibitors in both conditions. This evidence concerns the gene HSP90AB1 and glioblastoma.